Imnovid (Pomalidomide)

Imnovid is an immunomodulatory drug used in the management of plasma‑cell malignancies, specifically multiple myeloma.

• Relapsed/refractory multiple myeloma: improves disease control and extends progression‑free survival when used after prior therapies.

• Pomalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering substrate specificity and leading to degradation of transcription factors Ikaros and Aiolos. This results in reduced cytokine production, inhibition of angiogenesis, and induction of apoptosis in malignant plasma cells, while modulating the immune micro‑environment.

Adverse reactions to pomalidomide can vary in frequency and severity.

Common Side Effects

• Neutropenia: reduced neutrophil count increasing infection risk.
• Anemia: lowered red blood cell levels causing fatigue.
• Fatigue: general feeling of tiredness.
• Constipation: difficulty passing stools.
• Nausea: upset stomach and urge to vomit.
• Infections: heightened susceptibility to bacterial or viral infections.

Serious or Rare Side Effects

• Thromboembolic events: blood clots in veins or arteries.
• Severe rash or skin reactions: including Stevens‑Johnson syndrome.
• Elevated liver enzymes: indicating hepatic stress.
• Secondary primary malignancies: emergence of new cancers.
• Deep vein thrombosis or pulmonary embolism.
• Severe neutropenia leading to febrile neutropenia.

Before initiating therapy, clinicians should assess patient risk factors and monitor for potential complications.

• Blood count monitoring: perform regular CBC to detect neutropenia or anemia.
• Thromboembolic risk assessment: evaluate history of clotting disorders and consider prophylactic anticoagulation.
• Pregnancy avoidance: enforce strict contraception for women of child‑bearing potential.
• Hepatic function evaluation: check liver enzymes prior to and during treatment.
• Drug‑specific warnings: avoid concomitant use with known teratogens.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Pomalidomide may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase pomalidomide exposure.
• Teratogenic agents: concurrent use can heighten fetal risk.
• Immunosuppressants (e.g., high‑dose steroids): may amplify infection risk.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.
• Anticoagulants (e.g., warfarin, DOACs): monitor for altered clotting parameters.
• CYP1A2 inhibitors (e.g., fluvoxamine): may modestly increase levels.
• Vaccines: live vaccines should be avoided during therapy.